712 related articles for article (PubMed ID: 25131183)
21. Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?
Wu X; Wang J; Liu K; Zhu J; Zhang HL
Expert Opin Ther Targets; 2016; 20(2):209-22. PubMed ID: 26357850
[TBL] [Abstract][Full Text] [Related]
22. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3.
Zhu E; Wang X; Zheng B; Wang Q; Hao J; Chen S; Zhao Q; Zhao L; Wu Z; Yin Z
J Immunol; 2014 Jun; 192(12):5599-609. PubMed ID: 24842756
[TBL] [Abstract][Full Text] [Related]
23. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.
Zhu S; Qian Y
Clin Sci (Lond); 2012 Jun; 122(11):487-511. PubMed ID: 22324470
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
Guendisch U; Weiss J; Ecoeur F; Riker JC; Kaupmann K; Kallen J; Hintermann S; Orain D; Dawson J; Billich A; Guntermann C
PLoS One; 2017; 12(11):e0188391. PubMed ID: 29155882
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
[TBL] [Abstract][Full Text] [Related]
26. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.
Ding Q; Zhao M; Bai C; Yu B; Huang Z
BMC Immunol; 2015 May; 16():32. PubMed ID: 26021566
[TBL] [Abstract][Full Text] [Related]
28. In vivo regulation of gene expression and T helper type 17 differentiation by RORγt inverse agonists.
Skepner J; Trocha M; Ramesh R; Qu XA; Schmidt D; Baloglu E; Lobera M; Davis S; Nolan MA; Carlson TJ; Hill J; Ghosh S; Sundrud MS; Yang J
Immunology; 2015 Jul; 145(3):347-56. PubMed ID: 25604624
[TBL] [Abstract][Full Text] [Related]
29. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
Hu Y; Shen F; Crellin NK; Ouyang W
Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
[TBL] [Abstract][Full Text] [Related]
30. Autoimmune inflammation from the Th17 perspective.
Furuzawa-Carballeda J; Vargas-Rojas MI; Cabral AR
Autoimmun Rev; 2007 Jan; 6(3):169-75. PubMed ID: 17289553
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Fasching P; Stradner M; Graninger W; Dejaco C; Fessler J
Molecules; 2017 Jan; 22(1):. PubMed ID: 28098832
[TBL] [Abstract][Full Text] [Related]
32. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis.
Kang KY; Kim YK; Yi H; Kim J; Jung HR; Kim IJ; Cho JH; Park SH; Kim HY; Ju JH
Int Immunopharmacol; 2013 May; 16(1):85-92. PubMed ID: 23557965
[TBL] [Abstract][Full Text] [Related]
33. FOXP3 and RORγt: transcriptional regulation of Treg and Th17.
Chen Z; Lin F; Gao Y; Li Z; Zhang J; Xing Y; Deng Z; Yao Z; Tsun A; Li B
Int Immunopharmacol; 2011 May; 11(5):536-42. PubMed ID: 21081189
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
Yago T; Nanke Y; Kawamoto M; Yamanaka H; Kotake S
Cytokine; 2012 Aug; 59(2):252-7. PubMed ID: 22579702
[TBL] [Abstract][Full Text] [Related]
36. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.
Fujita-Sato S; Ito S; Isobe T; Ohyama T; Wakabayashi K; Morishita K; Ando O; Isono F
J Biol Chem; 2011 Sep; 286(36):31409-17. PubMed ID: 21733845
[TBL] [Abstract][Full Text] [Related]
38. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.
Wang X; Ma C; Wu J; Zhu J
J Neurosci Res; 2013 Jul; 91(7):871-81. PubMed ID: 23653308
[TBL] [Abstract][Full Text] [Related]
39. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.
Smith SH; Peredo CE; Takeda Y; Bui T; Neil J; Rickard D; Millerman E; Therrien JP; Nicodeme E; Brusq JM; Birault V; Viviani F; Hofland H; Jetten AM; Cote-Sierra J
PLoS One; 2016; 11(2):e0147979. PubMed ID: 26870941
[TBL] [Abstract][Full Text] [Related]
40. Novel therapeutic targets in rheumatoid arthritis.
Koenders MI; van den Berg WB
Trends Pharmacol Sci; 2015 Apr; 36(4):189-95. PubMed ID: 25732812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
